Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Biogen Ma Inc patents


Recent patent applications related to Biogen Ma Inc. Biogen Ma Inc is listed as an Agent/Assignee. Note: Biogen Ma Inc may have other listings under different names/spellings. We're not affiliated with Biogen Ma Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Biogen Ma Inc-related inventors


Bicyclic aryl sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at s1p receptors.. ... Biogen Ma Inc

Methods of treating progressive forms of multiple sclerosis

The present disclosure relates to methods of treating individuals suffering from progressive forms of multiple sclerosis.. . ... Biogen Ma Inc

Biaryl inhibitors of bruton's tyrosine kinase

The present invention provides compounds and compositions thereof which are useful as inhibitors of bruton's tyrosine kinase and which exhibit desirable characteristics for the same.. . ... Biogen Ma Inc

Methods and products for evaluating an immune response to a therapeutic protein

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a vla4 binding antibody (e.g., natalizumab).. ... Biogen Ma Inc

Anti-tnf-alpha polypeptide composition and use thereof

The invention provides a composition comprising an anti-tumor necrosis factor (tnf)-alpha polypeptide, wherein the composition produces a reduced level of immunogenicity when administered to a subject, as well as a treatment method involving the administration of the composition.. . ... Biogen Ma Inc

Bruton's tyrosine kinase inhibitors

The present invention provides compounds useful as inhibitors of btk, compositions thereof, and methods of using the same.. . ... Biogen Ma Inc

Methods for evaluating patients

Methods for evaluating subjects having conditions associated with loss of muscle function (e.g., a motor neuron disease, a neuromuscular disease, or a myopathy) by measuring muscle function (e.g., muscle strength) are disclosed.. . ... Biogen Ma Inc

Methods and compositions for detecting therapeutic nucleic acids

The present disclosure relates, in some aspects, to the field of nucleic acid detection. Disclosed herein are methods and compositions for detecting nucleic acids using synthetic single-stranded ribonucleic acids (rnas). ... Biogen Ma Inc

S1p modulating agents

Compounds of formula (i) or (ii) can modulate the activity of s1p receptors.. . ... Biogen Ma Inc

Biogen Ma Inc.

. . ... Biogen Ma Inc

Methods for improved measurements of brain volume and changes in brain volume

Methods of the disclosure may include obtaining a first set of medical images at a first time point and a second set of medical images at a second time point, each set including at least two medical images. First and second algorithms may be used to calculate, respectively, first and third brain volume (bv) values at the first time point based on two or more images from the first set of medical images and second and fourth bv values at the second time point based on two or more images from the second set of medical images. ... Biogen Ma Inc

Heterobicyclic sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at s1p receptors.. ... Biogen Ma Inc

Methods of treating multiple sclerosis

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.. ... Biogen Ma Inc

Methods of treating multiple sclerosis

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.. ... Biogen Ma Inc

12/21/17 / #20170363643

Compositions and methods for detection of smn protein in a subject and treatment of a subject

Disclosed herein are compounds, compositions and methods for modulating splicing of smn2 mrna in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. ... Biogen Ma Inc

12/21/17 / #20170362324

Humanized anti-alpha v beta 5 antibodies and uses thereof

Humanized antibodies and antibody fragments that bind to αvβ5 are disclosed. Also disclosed are methods of using the disclosed antibodies and antibody fragments to treat or prevent αvβ5-mediated diseases.. ... Biogen Ma Inc

12/21/17 / #20170360699

Apparatus for compound dispersion

Methods and apparatuses for dispersing a compound within the patient are described. In one embodiment, an effective amount of a compound may be present in the cerebrospinal fluid of a patient and a force may be applied to the torso of the patient sufficient to enhance the convection of the cerebrospinal fluid. ... Biogen Ma Inc

12/14/17 / #20170355771

Anti-gpiib/iiia antibodies and uses thereof

Antibodies and antibody fragments that specifically bind to glycoprotein iib/iiia (gpiib/iiia) are disclosed. Chimeric molecules comprising such antibodies or antigen-binding fragments are also disclosed. ... Biogen Ma Inc

12/14/17 / #20170355729

Methods and compositions for controlling antibody aggregation

Disclosed herein are methods of purifying monoclonal antibodies and related compositions.. . ... Biogen Ma Inc

12/14/17 / #20170354639

Diterpenoid derivatives and methods of use thereof

Provided herein are compounds of formula (i) and compositions containing the compounds. The compounds and compositions are useful in the methods of treating, amelioration or prophylaxix of diseases associated with nrf2/nf-κb pathways. ... Biogen Ma Inc

12/14/17 / #20170354630

Methods of treating multiple sclerosis

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.. ... Biogen Ma Inc

11/30/17 / #20170342152

Anti-glycoprotein iib/iiia antibodies

Antibodies and antigen-binding antibody fragments that bind to gpiib/iiia and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind gpiib/iiia on activated platelets while others do not show a preference for binding gpiib/iiia on resting versus activated platelets. ... Biogen Ma Inc

11/23/17 / #20170335000

Antibodies to vla-1

Antibodies that specifically bind to vla-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by vla-1 antibodies and their ligands, and vla-1 antagonists and agonists identified by using the structure coordinates of these structures.. ... Biogen Ma Inc

11/16/17 / #20170327861

Copper supplementation for control of glycosylation in mammalian cell culture process

The present invention pertains to a cell culture medium comprising copper as a media supplement, which was shown to control recombinant protein glycosylation and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.. ... Biogen Ma Inc

11/16/17 / #20170327786

Hypotaurine, gaba, beta-alanine, and choline for control of waste byproduct accumulation in mammalian cell culture process

The present invention pertains to a cell culture medium comprising hypotaurine, gaba, and/or beta-alanine or the combination of choline and hypotaurine, gaba, and/or beta-alanine as media supplements which is shown to control viability, growth, and waste byproduct accumulation. The present invention further pertains to a method of producing a polypeptide of interest in a large scale cell culture containing hypotaurine, gaba, and/or beta-alanine or the combination of choline and hypotaurine, gaba, and/or beta-alanine.. ... Biogen Ma Inc

10/26/17 / #20170306402

Systems and methods for characterization of multiple sclerosis

Methods and systems to characterize multiple sclerosis (ms) in a subject, e.g., in a subject having a progressive form of ms are disclosed.. . ... Biogen Ma Inc

10/12/17 / #20170290990

Injector lockout prevention device

A device that prevents the accidental activation and lockout of an autoinjector. In illustrative embodiments, a resistance unit is configured to resist deployment of the needle until a critical force is applied by the user to the autoinjector, at which point, the resistance of the resistance unit is overcome. ... Biogen Ma Inc

09/28/17 / #20170276659

Systems and methods for assessing therapeutic proteins

Systems and methods for assessing the oxidation status of a pharmaceutical preparations are provided herein. Methods provided herein are particularly useful for assessing pharmaceutical preparations comprising therapeutic proteins (e.g., therapeutic antibodies).. ... Biogen Ma Inc

09/14/17 / #20170260516

Optimized factor ix gene

The present invention provides codon optimized factor ix sequences, vectors and host cells comprising codon optimized factor ix sequences, polypeptides encoded by codon optimized factor ix sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized factor ix nucleic acid sequence or the polypeptide encoded thereby.. ... Biogen Ma Inc

08/31/17 / #20170247655

Methods of preventing and removing trisulfide bonds

The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. ... Biogen Ma Inc

08/31/17 / #20170247457

Methods of treating inflammatory and autoimmune diseases with natalizumab

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. ... Biogen Ma Inc

08/24/17 / #20170239280

Bicyclic aryl sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at s1p receptors.. ... Biogen Ma Inc

08/17/17 / #20170233485

Anti-cd40 antibodies and uses thereof

Antibodies and antibody fragments that bind to human cd40 and inhibit interaction between cd40 and its ligand, cd40l are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit hyperactivation of b or t cells and treat or prevent disorders such as autoimmune diseases.. ... Biogen Ma Inc

08/17/17 / #20170232111

Pegylation method

The present invention relates to a method for pegylating interferon beta.. . ... Biogen Ma Inc

07/27/17 / #20170209529

Fc receptor (fcrn) binding peptides and uses thereof

The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal fc receptor (fcrn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. ... Biogen Ma Inc

07/20/17 / #20170204093

Irak4 inhibiting agents

Provided are compounds of formula (i), or pharmaceutically acceptable salts thereof, and methods for their use and production.. . ... Biogen Ma Inc

07/20/17 / #20170202743

Medical metering device

A metering device that improves the aseptic transfer of powder and reconstitution fluid into the metering device for medical use. In some implementations, the metering device comprises a housing, containing a metering chamber that defines a volume. ... Biogen Ma Inc

07/13/17 / #20170197960

Atx modulating agents

Compounds of formula (i) can modulate the activity of autotaxin (atx).. . ... Biogen Ma Inc

06/29/17 / #the present invention provides compounds of formula (i) and (ii):

Biogen Ma Inc.

. . ... Biogen Ma Inc

06/22/17 / #20170174710

Compounds that are s1p modulating agents and/or atx modulating agents

Compounds of formula (i) can modulate the activity of one or more s1p receptors and/or the activity of autotaxin (atx).. . ... Biogen Ma Inc

06/22/17 / #20170173122

Lyophilized factor ix formulations

The present invention provides, among other things, pre-lyophilization formulations, reconstituted formulations, and lyophilate powder compositions comprising a factor ix (fix) polypeptide. The present invention also provides lyophilization methods for producing lyophilate powder comprising a fix polypeptide. ... Biogen Ma Inc

06/08/17 / #20170158687

Atx modulating agents

Disclosed are bicyclic aryl compounds of formula (i), that can modulate the activity of the autotaxin (atx) enzyme. This invention further relates to compounds that are atx inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.. ... Biogen Ma Inc

05/11/17 / #20170130186

Cross-scale modeling of bioreactor cultures using raman spectroscopy

Aspect of the disclosure relate to methods of assessing a bioreactor culture that involve determining a culture parameter of the manufacturing-scale bioreactor culture using a model that relates a raman spectrum to the culture parameter. Related bioreactor system are also provided.. ... Biogen Ma Inc

04/27/17 / #20170114382

Methods of increasing protein production in mammalian cells

Aspects of the present disclosure provide compositions and methods for increasing protein production in mammalian cells, e.g. Methods of increasing mammalian cell expression of a protein of interest, comprising culturing mammalian cells that overexpress a protein of interest and are modified to overexpress a gene encoding rab 11 or yap1, as well as mammalian cells that overexpress a protein of interest and which are modified to overexpress a gene encoding rab 11 or yap1.. ... Biogen Ma Inc

03/30/17 / #20170086763

Wearable medical detector

Various embodiments of medical detector systems as well as their methods of operation are disclosed. In one embodiment, one or more detectors are coupled to wearable structures for detecting at least a first tracer within a body portion. ... Biogen Ma Inc

03/16/17 / #20170073393

Factor viii chimeric proteins and uses thereof

The present invention provides a chimeric protein comprising a first polypeptide which comprises a fviii protein and a first ig constant region or a portion thereof and a second polypeptide which comprises a vwf protein comprising the d′ domain and d3 domain of vwf, a xten sequence having less than 288 amino acids in length, and a second ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.. ... Biogen Ma Inc

02/23/17 / #20170049904

Polyalkylene polymer compounds and uses thereof

The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis c.. ... Biogen Ma Inc

02/16/17 / #20170044538

Compositions and methods for modulation of smn2 splicing in a subject

Disclosed herein are compounds, compositions and methods for modulating splicing of smn2 mrna in a subject.. . ... Biogen Ma Inc

02/09/17 / #20170037126

Sp35 antibodies and uses thereof

Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. ... Biogen Ma Inc

02/02/17 / #20170029859

Medium supplements for improved process performance

The present invention pertains to a cell culture medium comprising dextran sulfate or a mixture of dextran sulfate and ferric citrate, and methods of using thereof. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with dextran sulfate or a mixture of dextran sulfate and ferric citrate.. ... Biogen Ma Inc

02/02/17 / #20170029518

Anti-bcma antibodies

This invention provides antibodies that recognize the b cell maturation antigen (bcma) and that bind naïve b cells, plasma cells, and/or memory b cells. The invention further provides methods for depleting naïve b cells, plasma cells, and memory b cells, and for treating b cell-related disorders, including lymphomas and autoimmune diseases.. ... Biogen Ma Inc

01/19/17 / #20170016919

Method of assessing risk of pml

The invention relates to methods of assessing a patient's risk of developing progressive multifocal leukoencephalopathy (pml).. . ... Biogen Ma Inc

01/05/17 / #20170000873

Dimethyl fumarate and vaccination regimens

Provided herein is a method of treating or preventing a disease or disorder (e.g., ms) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., dmf) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.. . ... Biogen Ma Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Biogen Ma Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Biogen Ma Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###